no code implementations • molecular therapy nucleic acids 2021 • Feng Xu, Xiaoling Huang, Yangyi Li, Yongsong Chen, and Ling Lin
This risk model based on the m6 A-based lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients.